ArticleBlood advances2023
Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia.
Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- Pediatric AML CAR T cell therapy.Molecular therapy. Oncology · 2026Review
- High expression of CD74 is associated with poor prognosis and tumor immune infiltration in Acute Myeloid Leukemia.Discover oncology · 2026Article
- ADC Conjugation Strategies: From Technological Evolution to a Practical Selection Framework.Pharmaceutics · 2026Review
- Targeting CD74 may mitigate immune-escape features and enhance BCMA CAR-T activity in preclinical models of relapsed/refractory multiple myeloma.Journal for immunotherapy of cancer · 2026Article
- Antibody-Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives.International journal of molecular sciences · 2026Review
- Advancements in antibody-drug conjugates as cancer therapeutics.Journal of the National Cancer Center · 2025Review
- Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy.Cancers · 2025Review
- Acute myeloid leukemia with RAM immunophenotype: A report of three patients and comprehensive literature review.EJHaem · 2025Article
- Network-based multi-class classifier to identify optimized gene networks for acute leukemia cell line classification.PloS one · 2025Article
- Moving forward in target antigen discovery for immunotherapy in acute myeloid leukemia.Haematologica · 2024Article
- CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group.Haematologica · 2024Article
- Slow-replicating leukemia cells represent a leukemia stem cell population with high cell-surface CD74 expression.Molecular oncology · 2024Article
- Single-cell transcriptomics and epigenomics unravel the role of monocytes in neuroblastoma bone marrow metastasis.Nature communications · 2023Article
- A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy.Frontiers in pharmacology · 2023Review
- Prognostic characteristics of immune subtypes associated with acute myeloid leukemia and their identification in cell subsets based on single-cell sequencing analysis.Frontiers in cell and developmental biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.